Press Releases Shanghai Henlius Biotech, Inc. OTC Markets

Equities

SGBCF

CNE100003N76

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

05-14	Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China	MT
05-14	Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	05-14	AQ
Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products	04-30	AQ
Shanghai Henlius Biotech, Inc. - IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI Approved by NMPA	04-18	AQ
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity	04-17	PR
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development	03-04	PR
Henlius Adalimumab Biosimilar Received sNDA Acceptance Notification from the NMPA	03-01	AQ
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene	01-12	AQ
Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	12-05	AQ
Henlius Xuhui Facility Passes Colombian GMP Inspection for HANLIKANG	11-29	AQ
Anaplastic Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	11-23	AQ
Henlius Deepens Collaboration with Intas to bring Henlius Novel anti-PD-1 mAb Serplulimab to Europe and India	30/10/23	AQ
Henlius Announces NMPA Approvals of Two ADC Candidates for IND	30/10/23	AQ
Shanghai Henlius Biotech, Inc. - First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe	26/10/23	AQ
Henlius Biotech, Inc. - Results from the Preclinical Study of HLX43, a Potential FIC PD-L1-Targeting ADC Released at 2023 ESMO	25/10/23	AQ
Henlius Xuhui Facility Passes PIC/S Member ANVISA GMP Inspection for HANLIKANG and HANQUYOU	23/10/23	AQ
Henlius Xuhui Facility Passes GMP Inspection for HANSIZHUANG by PIC/S Member BPOM	12/10/23	AQ
Henlius Novel Anti-PD-1 mAb HANSIZHUANG approved for the Treatment of ESCC	25/09/23	AQ
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius novel anti-PD-1 mAb HANSIZHUANG in MENA	13/09/23	AQ
Henlius Biotech, Inc. - HANQUYOU Marks 3rd Anniversary with Brilliant Achievements	28/07/23	AQ
Henlius Holds its 1st Overseas Scientific Advisory Board Meeting of 2023	28/06/23	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Shanghai Henlius Biotech, Inc. OTC Markets

Equities

SGBCF

CNE100003N76

Press Releases

Filters